News | September 21, 2023
Venus Remedies gets marketing approval for gemcitabine and docetaxel in Serbia
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated
